| Literature DB >> 22023931 |
Vickie Braithwaite1, Landing M A Jarjou, Gail R Goldberg, Helen Jones, John M Pettifor, Ann Prentice.
Abstract
We have previously reported on a case-series of children (n=46) with suspected calcium-deficiency rickets who presented in The Gambia with rickets-like bone deformities. Biochemical analyses discounted vitamin D-deficiency as an aetiological factor but indicated a perturbation of Ca-P metabolism involving low plasma phosphate and high circulating fibroblast growth factor-23 (FGF23) concentrations. A follow-up study was conducted 5 years after presentation to investigate possible associated factors and characterise recovery. 35 children were investigated at follow-up (RFU). Clinical assessment of bone deformities, overnight fasted 2 h urine and blood samples, 2-day weighed dietary records and 24 h urine collections were obtained. Age- and season-matched data from children from the local community (LC) were used to calculate standard deviation scores (SDS) for RFU children. None of the RFU children had radiological signs of active rickets. However, over half had residual leg deformities consistent with rickets. Dietary Ca intake (SDS-Ca=-0.52 (0.98) p=0.04), dietary Ca/P ratio (SDS-Ca/P=-0.80 (0.82) p=0.0008) and TmP:GFR (SDS-TmP:GFR=-0.48 (0.81) p=0.04) were significantly lower in RFU children compared with LC children and circulating FGF23 concentration was elevated in 19% of RFU children. Furthermore an inverse relationship was seen between haemoglobin and FGF23 (R(2)=25.8, p=0.004). This study has shown differences in biochemical and dietary profiles between Gambian children with a history of rickets-like bone deformities and children from the local community. This study provided evidence in support of the calcium deficiency hypothesis leading to urinary phosphate wasting and rickets and identified glomerular filtration rate and iron status as possible modulators of FGF23 metabolic pathways.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22023931 PMCID: PMC3459093 DOI: 10.1016/j.bone.2011.10.009
Source DB: PubMed Journal: Bone ISSN: 1873-2763 Impact factor: 4.398
Fig. 3Proposed mechanism relating rickets to urinary phosphate wasting caused by a chronically low calcium intake (reproduced from [2]).
Dietary assessment.
| Dietary intake per day | RFU children | LC children | SDS | |||||
|---|---|---|---|---|---|---|---|---|
| 6.0–9.9 years | 10.0–13.9 years | 14.0–22.0 years | 6.0–9.9 years | 10.0–13.9 years | 14.0–18.0 years | RFU-SDS | ||
| RFU v LC | ||||||||
| Calcium (mg)* | 182 (119, 279) | 208 (143, 304) | 233 (164, 332) | 217 (116, 406) | 471 (334, 665) | 268 (151, 474) | − 0.52 (0.98) | |
| Phosphorus (mg)* | 543 (381, 774) | 631 (554, 718) | 696 (587, 825) | 501 (312, 804) | 769 (584, 1,013) | 647 (404, 1,037) | 0.07 (0.75) | 0.7 |
| Ca/P (mmol/mmol) | 0.27 (0.08) | 0.26 (0.09) | 0.26 (0.04) | 0.34 (0.10) | 0.49 (0.15) | 0.32 (0.05) | − 0.80 (0.82) | |
| Energy (kJ) | 5560 (1637) | 7395 (853) | 8105 (442) | 5,864 (2179) | 7086 (1815) | 7473 (2701) | − 0.08 (0.70) | 0.7 |
| Protein (g) | 12.5 (1.8) | 11.1 (1.3) | 10.9 (0.1) | 36.6 (13.3) | 50.7 (10.1) | 51.8 (23.1) | − 0.29 (0.88) | 0.2 |
| Fibre (g) | 27.5 (7.9) | 34.6 (3.8) | 38.0 (15.2) | 31.8 (12.1) | 41.9 (11.6) | 40.5 (17.2) | − 0.07 (1.31) | 0.8 |
| Phytate (g)* | 0.72 (0.48, 1.09) | 0.84 (0.65, 1.09) | 0.73 (0.55, 0.97) | 0.72 (0.45, 1.16) | 0.98 (0.64, 1.49) | 0.89 (0.52, 1.52) | − 0.05 (0.83) | 0.8 |
For normally distributed data, the results are mean (SD); for positively skewed data (denoted by *) the results are geometric mean (− 1SD, + SD). The children are grouped into RFU children (rickets follow-up children) and LC children (local community children) and are then subdivided into age groups. n = number of children with data available. RFU-SDS (standard deviation scores) are mean (SD) and are calculated by [value RFU − meanLC) / SDLC]. p-value RFU v LC indicates the 2-sample Student's t-test p-value (RFU SDS/LC SDS).
Blood biochemistry.
| Fasting blood sample | RFU children | LC children | SDS | |||||
|---|---|---|---|---|---|---|---|---|
| 6.0–9.9 years | 10.0–13.9 years | 14.0–22.0 years | 6.0–9.9 years | 10.0–13.9 years | 14.0–18.0 years | RFU-SDS | ||
| n = 27 | n = 5 | n = 2 | n = 10 | n = 10 | n = 10 | RFU v LC | ||
| 25OHD (nmol/l) | 61 (14) | 57 (12) | 67 (12) | 61 (17) | 52 (18) | 46 (16) | 0.12 (0.86) | 0.6 |
| Corr-Ca (mmol/l) | 2.28 (0.08) | 2.29 (0.06) | 2.27 (0.03) | 2.33 (0.04) | 2.34 (0.07) | 2.34 (0.06) | − 0.97 (1.32) | |
| iCa (mmol/l) | 1.13 (0.04) | 1.14 (0.02) | 1.16 (0.05) | 1.14 (0.03) | 1.15 (0.03) | 1.14 (0.04) | − 0.33 (1.32) | 0.2 |
| P (mmol/l) | 1.53 (0.13) | 1.51 (0.23) | 1.06 (0.06) | 1.59 (0.20) | 1.41 (0.21) | 1.45 (0.18) | − 0.27 (0.87) | 0.2 |
| FGF23 (RU/ml)* | 65 (19, 223) | 54 (8, 392) | 63 (61, 65) | 54 (38, 76) | 39 (22, 69) | 49 (19, 125) | 0.54 (3.33) | 0.4 |
| 1,25(OH)2D (pmol/l)* | 246 (192, 315) | 323 (181, 578 ) | 247 (196, 317) | 236 (187,298) | 265 (197, 356) | 287 (224, 368) | 0.20 (1.21) | 0.5 |
| TALP (U/l)* | 299 (243, 369) | 332 (273, 405) | 133 (132, 133) | 280 (220, 356) | 264 (204, 342) | 252 (190, 335) | 0.21 (1.05) | 0.4 |
| PTH (pg/ml)* | 34.9 (12.7, 96.1) | 60.6 (39.7, 92.6) | 46.8 (45.8, 47.9) | 45.5 (29.4, 70.3) | 65.5 (40.5, 105.9) | 66.0 (44.2, 98.5) | − 0.55 (2.01) | 0.2 |
| Albumin (g/l) | 39.9 (2.5) | 39.1 (4.5) | 39.6 (0.3) | 37.8 (2.9) | 35.7 (3.5) | 36.8 (2.1) | 0.78 (0.90) | |
| AST (U/l)* | 34.5 (26.4, 45.3) | 25.3 (17.7, 36.1) | 23.8 (20.1, 28.5) | 24.9 (19.9, 30.9) | 25.0 (17.9, 34.8) | 20.0 (15.6, 25.8) | 1.68 (2.06) | |
| Bilirubin (μmol/l)* | 5.3 (3.6, 7.8) | 6.8 (5.4, 8.5) | 12.7 (4.6, 35.3) | 8.2 (6.6, 10.2) | 7.6 (5.1, 11.3) | 10.8 (6.7, 17.2) | − 1.63 (1.83) | |
| Cys C (mg/l)* | 0.85 (0.75, 0.96) | 0.79 (0.71, 0.87) | 0.80 (0.69, 0.92) | 0.78 (0.70, 0.87) | 0.76 (0.65, 0.88) | 0.80 (0.69, 0.93) | 0.58 (1.04) | |
| Cr (μmol/l) | 53.4 (5.1) | 56.6 (5.0) | 67.9 (4.4) | 52.4 (5.0) | 59.9 (5.7) | 64.0 (8.3) | 0.09 (1.00) | 0.7 |
| Hb (g/dl) | 12.6 (1.16) | 13.1 (1.5) | 13.5 (0.3) | 12.4 (1.3) | 12.9 (1.4) | 13.5 (1.2) | 0.21 (0.88) | 0.3 |
| cAMP (pmol/ml)* | 38.9 (26.2, 57.9) | 48.1 (20.8, 111.0) | 31.6 (27.2, 36.8) | 61.5 (39.2, 95.6) | 68.5 (40.1, 116.9) | 60.7 (46.3, 79.6) | − 1.04 (1.02) | |
| Mg (mmol/l) | 0.86 (0.05) | 0.78 (0.06) | 0.73 (0.03) | 0.85 (0.06) | 0.84 (0.05) | 0.85 (0.03) | − 0.20 (1.34) | 0.5 |
For normally distributed data, the results are mean (SD); for positively skewed data (denoted by *) the results are geometric mean (− 1SD, + SD). The children are grouped into RFU children (rickets follow-up children) and LC children (local community children) and are then subdivided into age groups. n = number of children with data available. RFU-SDS (standard deviation scores) are mean (SD) and are calculated by [value RFU − meanLC) / SDLC]. p-value RFU v LC indicates the 2-sample Student's t-test p-value (RFU SDS/LC SDS).
Fig. 1A. FGF23 concentrations of rickets follow-up children (RFU) () and local community children () and mean and SEM. The unadjusted 2-sample Student's t-test is p = 0.26. 19% of RFU have [FGF23] > 125 RU/ml, 3% of LC have [FGF23] > 125 RU/ml (χ2 = 3.67, p = 0.03). B. lnFGF23 of RFU at follow-up plotted against lnFGF23 at presentation. Broken line indicates the upper-limit assay reference range of 125 RU/ml. The equation of the line is lnFGF23 (RFU) = − 0.3 + 0.7lnFGF23 (presentation), R2 = 57.4% (p ≤ 0.0001) (unadjusted for age).
eGFR and mineral clearance.
| eGFR and mineral clearance | RFU children n = 33 | LC children n = 30 | SDS | |||||
|---|---|---|---|---|---|---|---|---|
| 6.0–9.9 years | 10.0–13.9 years | 14.0–22.0 years | 6.0–9.9 years | 10.0–13.9 years | 14.0–18.0 years | RFU-SDS | p-value | |
| Cys C-eGFR | 93.7 (16.3) | 103.2 (15.0) | 101.7 (20) | 104.1 (16.1) | 109.9 (24.6) | 101.3 (20.9) | − 0.55 (0.96) | |
| C-B-eGFR | 95.3 (8.1) | 100.3 (14.1) | 102.7 (8.0) | 99.2 (6.4) | 110.8 (7.5) | 111.5 (12.5) | − 0.74 (1.35) | |
| Schwarz-eGFR | 109.9 (9.7) | 117.6 (11.7) | 120.0 (0.4) | 111.1 (6.0) | 118.3 (47.4) | 138.5 (28.0) | − 0.19 (1.44) | 0.5 |
| CCr (μmol/min)* B | 0.53 (0.32, 0.85) | 0.56 (0.22, 1.43) | 0.69 (0.64, 0.75) | 0.46 (0.31, 0.69) | 0.54 (0.39, 0.74) | 0.70 (3.84, 1.27) | 0.27 (1.48) | 0.4 |
| P (mmol/2 h) * B | 0.68 (0.38, 1.21) | 0.54 (0.15, 1.97) | 0.68 (0.32, 1.42) | 0.48 (0.23, 0.96) | 0.46 (0.21, 0.98) | 0.54 (0.25, 1.12) | 0.44 (0.95) | 0.07 |
| CP (mmol/min) B | 0.004 (0.003) | 0.005 (0.003) | 0.006 (0.004) | 0.003 (0.002) | 0.003 (0.001) | 0.003 (0.002) | 0.54 (1.33) | 0.07 |
| TmP:GFR B | 1.60 (0.23) | 1.85 (0.33) | 1.06 (0.20) | 1.88 (0.45) | 1.63 (0.33) | 1.67 (0.36) | − 0.48 (0.81) | |
| Ca (mmol/2 h)* B | 0.03 (0.008, 0.10) | 0.02 (0.005, 0.12) | 0.15 (0.04, 0.52) | 0.02 (0.003, 0.16) | 0.04 (0.02, 0.11) | 0.06 (0.02, 0.12) | 0.07 (0.99) | 0.8 |
| CCa (nmol/min)* B | 0.09 (0.02, 0.10) | 0.10 (0.04, 0.55) | 0.50 (0.13, 1.73) | 0.09 (0.02, 0.35) | 0.16 (0.06, 0.36) | 0.24 (0.14, 0.44) | − 0.03 (1.08) | 0.9 |
| P (mmol/24 h)* B | 6.2 (3.9, 9.7) | 8.9 (6.7, 11.9) | 7.4 n=1 | 4.4 (2.6, 7.5) | 8.4 (5.3, 13.4) | 11.9 (9.1, 15.6) | 0.48 (0.93) | |
| CP (mmol/min) B | 0.003 (0.001) | 0.004 (0.002) | 0.004n=1 | 0.002 (0.001) | 0.004 (0.002) | 0.006 (0.001) | 0.60 (1.05) | |
| Ca (mmol/24 h)* B | 0.40 (0.12, 1.35) | 0.61 (0.22, 1.69) | 1.97n=1 | 0.83 (0.36, 1.89) | 0.64 (0.18, 2.20) | 0.57 (0.22, 1.43) | − 0.69 (1.44) | |
| CCa (nmol/min) * B | 0.12 (0.03, 0.43) | 0.19 (0.04, 0.74) | 0.65 (0.18, 2.23) | 0.24 (0.10, 0.55) | 0.16 (0.04, 0.53) | 0.19 (0.09, 0.44) | − 0.55 (1.60) | 0.1 |
For normally distributed data, the results are mean (SD); for positively skewed data (denoted by *) the results are geometric mean (− 1SD, + SD). The children are grouped into RFU children (rickets follow-up children) and LC children (local community children) and are then subdivided into age groups. n = number of children with data available. RFU-SDS (standard deviation scores) are mean (SD) and are calculated by [value RFU − meanLC) / SDLC]. p-value RFU v LC indicates 2-sample Student's t-test p-value (RFU SDS/LC SDS). eGFR (estimated glomerular filtration rate), Cys C (cystatin C), C–B (Counahn–Barret), CCr (creatinine clearance in mmol/min over 2 h), CP (phosphate clearance in mmol/min — 2 h), TmP:GFR (tubular maximum reabsorption of phosphate in mmol/l), CCa (calcium clearance in nmol/min — 2 h), CP (phosphate clearance in mmol/min — 24 h) and CCa (calcium clearance in nmol/min — 24 h). BIndicates variables corrected to an age-appropriate body surface area (BSAage) as calculated by mean BSA per LC age band.
Fig. 2Relationship between lnHb and lnFGF23 in rickets follow-up children (RFU) (A) and local community children (LC) (B). Age adjusted linear regression equations for RFU and LC children are lnFGF23 = 19.2–6.0 lnHb + 0.03 Age, R2 = 19.5% (p = 0.01) and lnFGF23 = 0.43 + 1.47 lnHb − 0.03 Age, R2 = 4.8% (p = 0.3) respectively. There is a significant lnHb × group interaction (p = 0.003).
Profile of RFU children with and without lasting leg deformities.
| Follow-up | SDS | ||
|---|---|---|---|
| Deformity | No deformity | No deformity | |
| v deformity | |||
| Calcium (mg) | − 0.48 (0.90) | − 0.51 (1.15) | 0.9 |
| Phosphorus (mg) | − 0.01 (0.69) | 0.21 (0.83) | 0.4 |
| Ca/P (mmol/mmol) | 0.8 | ||
| Energy (kJ) | − 0.13 (0.75) | 0.06 (0.65) | 0.4 |
| Protein (g) | 0.23 (0.87) | 0.42 (0.93) | 0.6 |
| Fibre (g) | − 0.27 (1.12) | 0.38 (1.50) | 0.2 |
| Phytate (g) | − 0.08 (0.84) | 0.07 (0.88) | 0.6 |
| 25OHD (nmol/l) | 0.11 (0.85) | 0.13 (0.91) | 0.9 |
| Corr-Ca (mmol/l) | 0.4 | ||
| iCa (mmol/l) | − 0.46 (0.99) | − 0.18 (1.63) | 0.6 |
| P (mmol/l) | − 0.25 (0.91) | − 0.30 (0.86) | 0.9 |
| FGF23 (RU/ml) | 1.24 (3.99) | − 0.26 (2.25) | 0.2 |
| 1,25(OH)2D (pmol/l) | 0.61 (1.32) | − 0.26 (0.88) | |
| TALP (U/l) | 0.30 (0.92) | 0.11 (1.20) | 0.6 |
| PTH (pg/ml) | 0.01 (1.71) | − 1.19 (2.34) | 0.1 |
| Albumin (g/l) | 0.9 | ||
| AST (U/l) | 0.4 | ||
| Bilirubin (μmol/l) | |||
| Cys C (mg/l) | 0.16 (1.10) | ||
| Cr (μmol/l) | 0.25 (1.05) | − 0.07 (0.94) | 0.3 |
| Hb (g/dl) | − 0.01 (0.73) | 0.37 (1.03) | 0.2 |
| cAMP (pmol/ml) | − | 0.6 | |
| Mg (mmol/l) | 0.29 (1.36) | ||
| Cys C eGFR | − 0.14 (1.05) | ||
| C-B eGFR | − 0.44 (1.49) | 0.2 | |
| CCr (μmol/min) B | 0.32 (1.23) | 0.21 (1.74) | 0.8 |
| P (mmol/2 h) B | 0.30 (1.17) | 0.4 | |
| CP (mmol/min) B | 0.52 (1.02) | 0.55 (1.64) | 0.9 |
| TmP:GFRB | − 0.37 (0.70) | 0.5 | |
| Ca (mmol/2 h) B | 0.03 (1.06) | 0.12 (0.93) | 0.8 |
| CCa (nmol/min) B | − 0.11 (1.24) | 0.06 (0.92) | 0.7 |
| P (mmol/24 h) B | 0.39 (1.02) | 0.5 | |
| CP (mmol/min) B | 0.53 (1.12) | 0.7 | |
| Ca (mmol/24 h) B | − 0.63 (1.69) | 0.8 | |
| CCa (nmol/min) B | − 0.83 (1.92) | − 0.27 (1.19) | 0.6 |
SD-score (as calculated by (value RFU − meanLC) / SDLC) with LC age bands) and 1 SD of RFU with and without lasting deformity.
p-value indicates 2-sample Student's t-test p-value between RFU with and without deformity. SDS in bold indicates p ≤ 0.05 between RFU group and LC. eGFR (estimated glomerular filtration rate), Cys C (cystatin C), C-B (Counahn–Barret), CCr (creatinine clearance in mmol/min over 2 h), CP (phosphate clearance in mmol/min — 2 h), TmP:GFR (tubular maximum reabsorption of phosphate in mmol/l), CCa (calcium clearance in nmol/min — 2 h), CP (phosphate clearance in mmol/min — 24 h) and CCa (calcium clearance in nmol/min — 24 h). BIndicates variables corrected to an age-appropriate body surface area (BSAage) as calculated by mean BSA per LC age band.